#TradFi交易分享挑战 Sudden layoffs! Johnson & Johnson cuts 56 more positions, completely abandons independent listing of the $20 billion orthopedics business!

On May 27, 2026, a WARN notice from New Jersey, USA, revealed that healthcare giant Johnson & Johnson will lay off 56 employees at its global headquarters in New Brunswick, with the layoffs officially taking effect on August 21, 2026. This is the first round of layoffs at the J&J campus this year, just a year after the 231 layoffs in fall 2024, indicating an accelerated pace of business restructuring.

Official response: layoffs are part of the orthopedics business spin-off measures Johnson & Johnson officially confirmed that this personnel optimization is a supporting move for the divestiture and strategic restructuring of the orthopedics business. The company stated that it will dynamically adjust organizational and cost structures, streamline redundant business costs, and ensure innovation investment and sustainable development. This adjustment follows J&J’s major restructuring plan announced in October 2025. At that time, J&J announced plans to spin off its core orthopedics division, DePuy Synthes, within 18-24 months, to operate independently. This division mainly produces orthopedic implants and supporting equipment, with revenue of $9.2 billion in fiscal year 2024, accounting for 29% of the total revenue of the Medical Technology segment.

Industry sources indicate that J&J has revised its plan for disposing of the orthopedics business. Starting February 2026, the company abandoned the plan to spin off and list the division separately, shifting to an overall sale of the segment, with an estimated business valuation exceeding $20 billion. Several leading private equity firms are now planning to jointly bid, and J&J is reviewing financial data to prepare for potential investors. The wave of layoffs at New Jersey pharmaceutical companies continues to intensify, and industry restructuring has become routine. J&J’s layoffs are not an isolated case.

As a hub for American pharmaceutical companies, New Jersey has recently seen major firms initiate layoffs and organizational adjustments intensively, making cost reduction and restructuring a norm in the industry. Novartis’s East Hanover headquarters in the US completed three rounds of layoffs in 2026, reducing a total of 174 employees, continuing the global plan announced in 2022 to cut 8,000 jobs. In March 2025, the campus once laid off 427 employees in a single round, highlighting significant restructuring efforts. BMS (Bristol-Myers Squibb) has implemented even larger cost-cutting measures, with two rounds of layoffs totaling 453 employees at the Lawrenceville site since 2025, with annual layoffs exceeding 1,700. The company plans to save over $2 billion by 2027 through ongoing profit structure optimization. Additionally, in May 2026, Amicus Therapeutics, acquired by BioMarin for $4.8 billion, laid off 58 employees in New Jersey, exemplifying post-merger integration and optimization in the pharmaceutical industry.

Industry observation: strategic focus and cost reduction as core drivers
Industry analysts believe that the global leading pharmaceutical companies are consolidating layoffs and optimization around two main trends: focusing on high-value sectors, optimizing business layouts, and strictly controlling operating costs to stabilize profitability. For J&J, sluggish growth in the orthopedics segment is the primary reason for divestment. In 2025, this segment’s growth was only 1.1%, ranking last among the four major medical technology sectors, while cardiovascular growth reached 12.6%. After divesting the orthopedics business, J&J will focus on three high-growth areas: cardiovascular, surgical, and vision, with the proportion of high-value assets increasing from 50% to over 70%, significantly strengthening core competitiveness.

Currently, the global pharmaceutical industry faces rising R&D costs, patent expirations, and intensified market competition. Streamlining organizations and cutting costs to balance R&D and profitability has become a common strategy for international pharma companies to cope with industry cycles and ensure steady development. As of now, J&J has not announced the final disposal plan for its orthopedics business or subsequent personnel adjustments. As cost-cutting and restructuring efforts continue, the wave of structural optimization in the global pharma industry is expected to persist. $JNJ